Gossamer Bio (GOSS) Set to Announce Earnings on Wednesday

Gossamer Bio (NASDAQ:GOSS) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($3.9340) per share and revenue of $12.16 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Gossamer Bio Stock Up 6.8%

Shares of NASDAQ GOSS opened at $9.77 on Wednesday. Gossamer Bio has a 1-year low of $8.29 and a 1-year high of $309.60. The business’s fifty day moving average price is $11.36 and its two-hundred day moving average price is $45.82.

Wall Street Analysts Forecast Growth

GOSS has been the subject of several analyst reports. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Chardan Capital restated a “buy” rating on shares of Gossamer Bio in a research report on Monday. Finally, Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research note on Tuesday, July 28th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Gossamer Bio has a consensus rating of “Hold” and an average price target of $256.00.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.